lx9851

LX9851 is an orally delivered small molecule drug candidate developed for the treatment of obesity and associated cardiometabolic disorders. It acts as a potent and selective inhibitor of acyl-CoA synthetase long-chain family member 5 (ACSL5), an enzyme involved in fat accumulation and energy balance. By inhibiting ACSL5, LX9851 activates the ileal brake mechanism—a physiological process that delays gastric emptying and suppresses appetite by increasing satiety. This dual action addresses both metabolic regulation and appetite control. Preclinical studies have shown that LX9851 reduces weight, food intake, and fat mass in diet-induced obese mice, with enhanced effects when combined with semaglutide (a GLP-1 agonist). The drug also mitigates weight regain after discontinuation of GLP-1 therapy and improves liver steatosis. Originally discovered by Lexicon Pharmaceuticals, development rights have been licensed to Novo Nordisk for further clinical advancement[3][4][5][6][7].